From standardization of imaging techniques to more reproducible and cost-effective organoid culture media
Organoids have the potential to revolutionize current drug discovery approaches, enhance the physiological relevance of in vitro disease models, and deliver on the promise of precision medicine. But, as with any new technology, there are a number of hurdles to overcome as pharma and biotech look to scale-up their organoid models and incorporate them routinely into their assay workflows.
CytoSMART and Qkine have partnered with organoid pioneers from both academia and industry to facilitate an open and collaborative discussion about the key challenges facing pharma and biotech companies as they approach this pivotal stage of their organoid R&D programs.
In this free webinar, we’ll be covering:
- The opportunities organoids offer and the challenges faced when scaling up applications, including standardization of imaging techniques
- The need for more reproducible, cost-effective chemically-defined organoid culture media to support the seamless transition from bench to clinical-based applications
- The latest imaging technologies from CytoSMART to enhance organoid research
- How Qkine is optimizing key organoid growth factors for more reproducible, animal-free organoid culture media
- Q&A session with organoid experts from Cold Spring Harbor Laboratory, Stemnovate, and Hubrecht Organoid Technology (HUB)
Organoid webinar's details
- 1 hour 15 min including Q&A
- Free to register
Don’t miss out!
Organoid webinar's speakers
Dr. René M. Overmeer, Head of Assay Development & Automation at Hubrecht Organoid Technology. Presentation: "Reliable High throughput screening using organoids"
Dennis Plenker, Ph.D., Research Investigator Laboratory of Dr. David Tuveson, Technical Manager Organoid Facility. Presentation: "Human organoid growth conditions – from media to organoid cultures"
Dr. Ruchi Sharma, CEO & Founder Stemnovate Limited. Presentation: "Tissue engineering, organoids or organ systems: challenges and opportunities"
Dr. René M. Overmeer received his Ph.D. in Biology from the Leiden University Medical Center on a molecular study of DNA damage repair. He subsequently moved to University Medical Center Utrecht to do his Post Doc studying Ras/Rap cancer signaling. During this period, he started working with adult stem cell-derived Organoid Technology and developed the first drug screens together with the group of Hans Clevers. He continued this work at Hubrecht Organoid Technology (HUB) where he became responsible for the development of new assays and automation processes.
Dr. Dennis Plenker studied molecular biomedicine at the University of Bonn, Germany, and performed drug screens in primary glioblastoma cells for his diploma thesis. For his Ph.D. he transferred to the Department of Translational Genomics at the University of Cologne and characterized the first oncogenic gene fusion that involves a ligand (CD74-NRG1). Dennis did a postdoc in the Department of Molecular Pathology where he showed how to effectively treat RET-fusion positive tumors and how to treat tumors with rearrangements in the MET oncogene. Dennis moved to CSHL in 2017 and manages the human organoid platform in the Tuveson lab focusing on advancing organoid technology and understanding resistance in pancreatic cancer.
Dr. Ruchi Sharma is driven by her passion for taking the benefits of research and applying them to products and technology in order to make a significant and positive difference in the real world. She is one to watch entrepreneur of 2020 in UK and is leading prestigious grants and multinational partnerships. Dr. Sharma obtained a PhD from the world-renowned Roslin Institute at the University of Edinburgh, followed by a post-doctorate in the exciting field of cellular reprogramming at the University of Cambridge. With a firm focus on partnerships and collaboration, Dr. Sharma firmly believes that together, we can create a better world.
Organoid webinar's hosts
Dr. Inge Thijssen van Loosdregt, Field Application Engineer, CytoSMART. Presentation: "Enhancing organoid research using novel bright-field imaging devices"
Rob Nixon, Head of Commercial, Qkine. Presentation: "Re-defining growth factor & cytokine biochemical quality"
Dr. Inge Thijssen van Loosdregt is a Field Application Engineer at CytoSMART with a background in life sciences. She has obtained her Ph.D. in soft tissue engineering and mechanobiology at the Eindhoven University of Technology. Inge’s Ph.D. work focused on understanding the forces generated by fibroblasts in order to eventually optimize the design of tissue-engineered heart valves. As a Field Application Engineering, she tests CytoSMART's devices in the lab and works with R&D to keep optimizing and validating the devices in order to fulfill the needs of life science researchers.
Rob Nixon has a strong commercial background in the life science segment with a track record of building and coaching highly successful sales teams. Educated at the University of Manchester, studying BSc (Hons) Medical Biochemistry, he began life at Biotest UK before the pharmaceutical microbiology business was acquired by Merck Millipore. Having worked for Merck in several northern European roles within the laboratory reagents business for over 10 years, he moved to GE Healthcare Life Science to build and drive a new EMEA team focused on applied markets, with a particular focus on the rapidly growing and highly relevant point-of-care lateral flow test market. Latterly, Rob developed a global distributor network for Jellagen’s next-generation collagen to channel into the research market for stem cell and regenerative medicine applications. Rob joined Qkine in April 2020 to implement the commercial go-to-market strategy, channeling Qkine’s growth factor & cytokine portfolio for stem cell culture and organoid research applications.